Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Kati, Erdmann"'
Autor:
Konrad Grützmann, Karsten Salomo, Alexander Krüger, Andrea Lohse-Fischer, Kati Erdmann, Michael Seifert, Gustavo Baretton, Daniela Aust, Doreen William, Evelin Schröck, Christian Thomas, Susanne Füssel
Publikováno v:
Biology Direct, Vol 19, Iss 1, Pp 1-15 (2024)
Abstract Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC with high rates of metastasis. Targeted therapies such as tyrosine kinase and checkpoint inhibitors have improved treatment success, but therapy-related sid
Externí odkaz:
https://doaj.org/article/01f8ed8b79a74027a6c7059899fbf7ed
Autor:
Benedikt Hoeh, Cristina Cano Garcia, Severine Banek, Niklas Klümper, Alexander Cox, Jörg Ellinger, Philipp Schmucker, Oliver Hahn, Angelika Mattigk, Friedemann Zengerling, Philippe Becker, Kati Erdmann, Bjoern Thorben Buerk, Luka Flegar, Johannes Huber, Charis Kalogirou, Philip Zeuschner
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 10, Pp n/a-n/a (2023)
Abstract Objectives Although biomarkers predicting therapy response in first‐line metastatic renal carcinoma (mRCC) therapy remain to be defined, C‐reactive protein (CRP) kinetics have recently been associated with immunotherapy (IO) response. He
Externí odkaz:
https://doaj.org/article/10187729c1d240028467b94f1f3790c9
Autor:
Margarita Melnikova, Ulrike Sophie Wauer, Diana Mendus, Ralf Axel Hilger, Trudy G. Oliver, Kim Mercer, Björn Oliver Gohlke, Kati Erdmann, Dieter Niederacher, Hans Neubauer, Paul Buderath, Pauline Wimberger, Jan Dominik Kuhlmann, Jürgen Thomale
Publikováno v:
Molecular Oncology, Vol 14, Iss 4, Pp 686-703 (2020)
Platinum‐based compounds remain a well‐established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type‐specific toxicity and the clinical responsi
Externí odkaz:
https://doaj.org/article/c92a25a31abc4582925f02044ae84d0e
Autor:
Dinah Linke, Lukas Donix, Claudia Peitzsch, Holger H. H. Erb, Anna Dubrovska, Manuel Pfeifer, Christian Thomas, Susanne Fuessel, Kati Erdmann
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 666 (2022)
Docetaxel (DTX) is a mainstay in the treatment of metastatic prostate cancer. Failure of DTX therapy is often associated with multidrug resistance caused by overexpression of efflux membrane transporters of the ABC family such as the glycoprotein ABC
Externí odkaz:
https://doaj.org/article/e6f8e7868a164829a0c4b73361f74359
Autor:
Alexander Schulz, Ielizaveta Gorodetska, Rayk Behrendt, Susanne Fuessel, Kati Erdmann, Sarah Foerster, Kaustubh Datta, Thomas Mayr, Anna Dubrovska, Michael H. Muders
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
Neuropilin-2 (NRP2) is a prognostic indicator for reduced survival in bladder cancer (BCa) patients. Together with its major ligand, vascular endothelial growth factor (VEGF)-C, NRP2 expression is a predictive factor for treatment outcome in response
Externí odkaz:
https://doaj.org/article/a885c977c66443608873400f9081394f
Autor:
Doreen William, Kati Erdmann, Jonas Ottemöller, Anastasios Mangelis, Catleen Conrad, Mirko Peitzsch, Evelin Schröck, Graeme Eisenhofer, Aristeidis Zacharis, Susanne Füssel, Daniela Aust, Barbara Klink, Susan Richter
Publikováno v:
Metabolites, Vol 11, Iss 11, p 764 (2021)
Renal cell carcinoma (RCC) is among the 10 most common cancer entities and can be categorised into distinct subtypes by differential expression of Krebs cycle genes. We investigated the predictive value of several targeted metabolites with regards to
Externí odkaz:
https://doaj.org/article/737c8718eab247f0abc5488e82bb525a
Autor:
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, Kati Erdmann, Susanne Füssel, Theresa Link, Andreas du Bois, Stefan Kommoss, Florian Heitz, Jalid Sehouli, Rainer Kimmig, Nikolaus de Gregorio, Barbara Schmalfeldt, Tjoung-Won Park-Simon, Klaus Baumann, Felix Hilpert, Marcel Grube, Willibald Schröder, Alexander Burges, Antje Belau, Lars Hanker, Jan Dominik Kuhlmann
Publikováno v:
Clinical Cancer Research. 28:4660-4668
Purpose: The identification of a robust IHC marker to predict the response to antiangiogenic bevacizumab in ovarian cancer is of high clinical interest. VEGF-A, the molecular target of bevacizumab, is expressed as multiple isoforms with pro- or antia
Autor:
Bastian Keck, Angelika Borkowetz, Julia Poellmann, Thilo Jansen, Moritz Fischer, Susanne Fuessel, Andreas Kahlmeyer, Manfred Wirth, Johannes Huber, Alexander Cavallaro, Matthias Hammon, Ivan Platzek, Arndt Hartmann, Gustavo Baretton, Frank Kunath, Danijel Sikic, Helge Taubert, Bernd Wullich, Kati Erdmann, Sven Wach
Publikováno v:
Cells, Vol 10, Iss 6, p 1315 (2021)
Multiparametric MRI (mpMRI) and targeted biopsy of the prostate enhance the tumor detection rate. However, the prediction of clinically significant prostate cancer (PCa) is still limited. Our study tested the additional value of serum levels of selec
Externí odkaz:
https://doaj.org/article/a71bd8aa6f6e4272b3d8ca217a30143f
Autor:
Anika Kaufmann, Silke Hampel, Christiane Rieger, David Kunhardt, Darja Schendel, Susanne Füssel, Bernd Schwenzer, Kati Erdmann
Publikováno v:
Journal of Nanobiotechnology, Vol 15, Iss 1, Pp 1-15 (2017)
Abstract Background In addition to conventional chemotherapeutics, nucleic acid-based therapeutics like antisense oligodeoxynucleotides (AS-ODN) represent a novel approach for the treatment of bladder cancer (BCa). An efficient delivery of AS-ODN to
Externí odkaz:
https://doaj.org/article/abd1a16f90734ac8967c3632a5b55d23
Publikováno v:
Beilstein Journal of Nanotechnology, Vol 8, Iss 1, Pp 1307-1317 (2017)
We have previously shown that carbon nanofibers (CNFs) and carbon nanotubes (CNTs) can sensitize prostate cancer (PCa) cells to platinum-based chemotherapeutics. In order to further verify this concept and to avoid a bias, the present study investiga
Externí odkaz:
https://doaj.org/article/eb63cc11343740d2bd7cda1ec3a2d4da